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Introduction
Ovarian cancer is the primary cause of gynecologic
cancer death in the United States1. The overall 5-year
survival rate is about 46% and has remained unchanged
for 25 years. Epithelial ovarian neoplasms comprise
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SUMMARY
Background: Human ovarian carcinoma is a silent killer. Most patients with human ovarian carcinoma are
diagnosed in the advanced stages. Currently, no effective means of early detection are available. Identifying
genes that distinguish early cancers from normal tissue may provide insight to the initiation and progression of
ovarian cancer.
Methods: A large-scale gene expression profiling using 9,600 genes-complementary DNA array to study ovarian
tumors was conducted. We analyzed 13 benign tumors, 22 invasive cancers (seven stage I and 15 stage III), and
16 normal ovaries. Cluster analysis revealed two major groups: the early-stage cluster that included 13 benign
tumors and seven stage I cancers; and the late-stage cluster that included all stage III cancers.
Results: There were 433 upregulated and 60 downregulated genes from the early-stage cluster, and 395 upreg-
ulated and 101 downregulated genes from the late-stage cluster. These genes showed altered functions for
tumor/cancers, functions such as cell growth, cell cycle control, differentiation, signaling, apoptosis, ion trans-
port, and morphogenesis. Of most interest is the downregulation of nuclear receptor proteins. Differentially
expressed genes between early-stage cluster and late-stage clusters were identified. We found 90 genes prefer-
entially overly expressed and 165 genes relatively downregulated at late-stage cancers. The advanced cancer
appears differently from early-stage cancer in cell growth, cell adhesion, hormone activity, morphology, and
cell–cell signaling compared with benign or early-stage cancer. Of particular interest are enzymes correspond-
ing to pteridine biosynthesis, reported for the first time in this study. Real-time reverse transcription poly-
merase chain reaction showed that GCH1, KRT18, H3F3A, and MYBL2 were overly expressed in all cancer
tissues, while MDFI, ARP3BETA, COL16A1, and MLN discriminated late-stage from early-stage cancers.
Conclusion: The microarray provides valuable resources for comparing expression profiles of cancers at various
stages and helps research the diagnosis and mechanism of ovarian cancer. [International Journal of
Gerontology 2009; 3(3): 163–169]
Key Words: borderline malignancy, expression profile, microarray, ovarian tumor, real-time reverse 
transcription polymerase chain reaction
*Correspondence to: Dr Chi-Wei Wang, Department
of Internal Medicine, Ben Tang Cheng Ching Hospi-
tal, 718, Zhongzheng Road, Wufeng Township,
Taichung County 413, Taiwan.
E-mail: singaboy@gmail.com
Accepted: March 8, 2009
■ ORIGINAL ARTICLE
© 2009 Elsevier.
97% of ovarian tumor cases2. They are classified into
three main groups: benign, borderline, and invasive.
Microarray simultaneously presents the expression
of tens of thousands of genes on a genomic scale3,4.
This technology enables cancer researchers to com-
pare gene expression between normal and malignant
tissues and to quickly identify genes that are dif-
ferentially regulated during cancerous progression5.
Microarray data sets can also be used to categorize
tumors on the basis of their expression profile and
provide useful biologic, diagnostic and prognostic
information for mechanistic studies.
Genomic expression for ovarian cancers has been
reported from many groups6–11. A key emphasis in
these studies has been the identification of gene prod-
ucts that could act as ovarian cancer specific markers.
Identifying genes that distinguish early cancers from
normal tissue may also provide insight to the initiation
and progression of ovarian cancer. Microarray is cer-
tainly a promising tool and is being used extensively.
Identifying genes whose expression is specific to
the pathogenic staging of ovarian cancer will help to
define the sequential events from benign to invasive
tumors. Further identifying the molecular signature
for each stage may aid the development of molecular
tools for diagnosis and therapy.
We describe the use of signal-amplified comple-
mentary DNA (cDNA) microarray to identify transcripts
that specify stage-specific expression in ovarian tumor/
cancer tissues. Functional annotation for the differen-
tially expressed genes reveals key features that signify
each pathologic stage. Additionally, the molecular fin-
gerprinting provides insights into the functional study
of ovarian cancer.
Materials and Methods
Specimens
This study was approved by the review board of China
Medical University Hospital in accord with institutional
guideline for human subjects. Tissues were obtained
from patients after obtaining written informed consent.
The ovarian tissues were collected between 2001 and
2003 from the surgical and pathologic units at China
Medical University Hospital. After surgery, tissue sections
were snap-frozen in liquid nitrogen and an adjacent
section was taken for the pathologist’s examination. In
most cases, the epithelial portion of normal ovarian
tissue was collected, avoiding the small follicular cyst
and corpus luteum. All tissues once removed were
carefully dissected, divided, and immediately snap-
frozen. All tumor specimens were examined for tumor
cell content and the absence of necrosis. Surgical stag-
ing was determined according to the FIGO system12.
Specimens which gave rise to sufficient amount of total
RNA for microarray and follow-up real-time reverse
transcription polymerase chain reaction (RT-PCR) were
described further. The 13 benign tumors included mucin-
ous cystadenoma, serous cystadenoma, endometrioma,
and mature teratoma. The histologic subtypes of the
ovarian carcinomas included 12 serous cystadenocar-
cinomas, three mucinous cystadenocarcinomas, five
endometrioid adenocarcinomas, and two clear cells.
The stage distribution for the 22 ovarian carcinomas
included seven stage I, and 15 stage III. Final collec-
tion included 16 normal ovaries, seven ovarian carci-
nomas at stage I, and 15 carcinomas at stage III.
Microarray protocol
All microarray procedures were performed in a dust/
climate control laboratory at China Medical University.
These included polymerase chain reaction (PCR) am-
plification, spotting, post-spotting processing, RNA
extraction, probe preparation, hybridization, and post-
hybridization experiments. Microarray design, experi-
mental procedures, data processing, and data presen-
tation were carefully performed according to MIAME
guidelines13. We used a microarray consisting of 9,600
sequence-verified human cDNA.
Total RNA was extracted using protocol supplied with
TRI-reagent (Molecular Research Center, Inc., Cincinnati,
OH, USA). Quality of RNA was examined by agarose gel
electrophoresis, and by OD 260/280 ratio (> 1.8). For
typical labeling reaction, 0.5–10 μg of total RNA was
annealed with 0.5 μg of poly(dT)14 in a total volume of
20 μL. The cDNA synthesis was performed in a 50-μL
mixture containing annealed RNA, 0.5 mM each of
deoxyadenosine triphosphate, deoxycytidine triphos-
phate (dCTP), and deoxythymosine triphosphate; 40μM
each of dCTP and Cy3-dCTP or Cy5-dCTP (Roche, Netley,
NJ, USA); 10 mM of dithiothreitol; 1 unit of ribonucle-
ase inhibitor (Invitrogen, Carlsbad, CA, USA); and 50
units of SuperScript II RT (Invitrogen) in 1X Superscript
II RT reaction buffer. The mixture was incubated for 90
minutes at 42°C in the dark and terminated by heating
at 95°C for 5 minutes. The RNA was degraded by addi-
tion of 5.5 μL of 3N NaOH, and incubated at 50°C for
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30 minutes. The mixture was neutralized by addition
of 5.5 μL of 3M acetic acid, and filter-purified by
Microcon YM-100 (Amicon Co., Billerica, MA, USA). The
final volume was 30 μL. The microarray was prehy-
bridized in 30 mL of prehybridization buffer containing
25% formamide, 5X saline sodium citrate (SSC), 0.1%
sodium dodecyl sulfate (SDS), and 0.1 mg/mL bovine
serum albumin in 50-mL conical tube at 42°C for 1 hour.
The labeled probe was mixed with 20 μg of poly(dA)10
and 20 μg of human placental DNA (Human Cot-1
DNA; Invitrogen), and denatured at 95°C for 5 minutes.
The denatured probe was dried and suspended in
20 μL of prehybridization buffer. Hybridization was
performed in a Corning hybridization chamber
(Sigma-Aldrich, St. Louis, MO, USA), and incubated at
42°C for 12–16 hours. The slide was washed twice with
30 mL of 2X SSC, 0.1% SDS for 5 minutes at room tem-
perature, followed by three washes at 20 minutes each
with 30 mL of 0.1X SSC and 0.1% SDS at 42°C. All wash-
ing procedures were performed in 50-mL conical tubes
with gentle shaking. Fluorescence scanning was per-
formed using an Axon Genepix 4000B (Molecular
Devices, Sunnyvale, CA, USA). The fluorescent image was
processed by GenePix Pro 3.0 (Molecular Devices) to
obtain a raw expression data set. Mean intensity and
mean background intensity were utilized for data pro-
cessing. We employed global array intensity for normal-
ization controls. Nonlinear normalization using locally
weighted linear regression was performed15. Logarith-
mic ratios based on 2 were calculated accordingly.
Functional annotation
Functional annotation for differentially expressed
genes was performed by the EASE program. This was
downloaded from the DAVID (Database for Annotation,
Visualization, and Integrated Discovery) Web page
(http://david.abcc.ncifcrf.gov/). Functional principles,
i.e., cellular component, molecular function and bio-
logic function, were provided from the LocusLink
database (superseded by Entrez Gene; http://www.
ncbi.nlm.nih.gov/sites/entrez?db=gene) and incorpo-
rated into the EASE program. The LocusLink identifiers
associated with genes on the microarray were updated
using database provided by Swiss-Prot (http://www.
expasy.ch/sprot/). A total of 8,262 genes out of 9,600
genes on microarray was associated with a unique
LocusLink number and served as the basis for further
statistical analysis. Lists of identifiers containing dif-
ferentially expressed genes were generated.
Real-time RT-PCR
Real-time PCR analysis was performed using an iQ
SYBR Green Supermix (Bio-Rad, Hercules, CA, USA)
according to manufacture’s instructions, with the 
specific primer pairs for selected genes and primer
pairs for ribosomal protein L18 as the reference gene.
PCR primers were designed and synthesized according
to the published sequence of human genes from
GenBank. Threshold cycle number (Ct) was measured
using the iCycler and its associated software (Bio-Rad)16.
Relative transcript quantities were calculated by the
Ct method using ribosomal protein L18 as refer-
ence gene amplified from samples. Ct is the differ-
ence in threshold cycles of the sample messenger
RNAs relative to ribosomal protein L18 messenger
RNA. Ct is the difference between Ct of normal
control and Ct of tumor sample. Values for fold-
induction varied less than 5% among replicates. Six
specimens from early-stage and late-stage cluster were
selected.
Results
We performed microarray experiments on 13 benign
tumors, 22 invasive cancers (seven stage I cancers and
15 stage III cancers), and 16 normal ovaries.  Hierarchi-
cal clustering analysis was performed using ratios
derived from 9,600 genes (Figure 1). We identified two
well-separated clusters. All benign tumors and stage I
ovarian cancers were mingled and grouped to the
early-staged cluster. All stage III cancers were grouped
to the second cluster, the late-stage cluster. Cluster
analysis of our microarray data was capable of distin-
guishing late-stage cancers from benign/early-stage
cancer; however, the inability of microarray data to
distinguish benign from stage I cancer is not necessary
to indicate biologic identity between these two clinically
distinct groups. It merely indicates that the expression
profiles of both types of tumors were more distinct com-
pared with stage III cancer than to each other. To com-
pare the expression profiles, we temporarily assigned
these two groups into early- and late-stage clusters.
Pairwise correlation coefficients were calculated to
quantify similarity between different tissue types. The
correlation coefficient was 0.898 between benign and
stage I cancer, 0.532 between benign and stage III can-
cer and 0.643 between stage I and III cancer. The
results indicated that benign and stage I cancer were
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highly similar and stage III cancer emerged as a single
entity with low degrees of similarity to either benign
or stage I cancer.
The inability of clustering to distinguish stage I
cancer from benign tumor indicated the relatively
minor change at the transcriptional level from benign
to stage I compared with stages I and II. The results do
not imply molecular identity. However, the results are
consistent with the clinical outcome for benign tumor
and stage I cancer. The 5-year survival rate of stage I
cancer is 76–93%, which is significantly different from
29–59% of stage III cancer patients17.
For the early-stage cluster, significance analysis of
microarray (SAM) was applied to identify 469 upregu-
lated genes and 66 downregulated genes. The median
number of false significant genes was 0.34, delta was
2.87, and minimum fold change was set to 2.4 (double
the standard deviation). After discarding unknown
sequences, 427 upregulated and 57 downregulated
genes were derived.
For the late-stage cluster, SAM analysis was applied
to identify 1,163 upregulated genes and 518 downreg-
ulated genes. The median number of false significant
genes was 0.34, and delta was 2.87. Three hundred and
ninety-nine upregulated and 60 downregulated genes
were recognized when setting the minimum fold
change to 2.4.
Discussion
The differentially expressed genes of the early-stage
cluster revealed rearrangement in cell proliferation,
cell cycle control, and cell differentiation; the genes of
the late-stage cluster were involved in cell–cell signal-
ing, apoptosis, metal ion transport, morphogenesis,
and, most interestingly, pteridine biosynthesis (a pre-
viously unreported finding). Guanosine triphosphate
(GTP) cyclohydrolase 1 (GCH1) catalyzes the conversion
of GTP to D-erythro-7,8-dihydroneopterin triphosphate,
the first and rate-limiting step in tetrahydrobiopterin
biosynthesis. Tetrahydrobiopterin is an essential cofac-
tor for three aromatic amino acid monooxygenases:
phenylalanine, tyrosine and tryptophan hydroxylases.
Animals can synthesize tetrahydrobiopterin in vivo
from GTP through several enzymatic reactions. Quinoid
dihydropteridine reductase and flavin adenine dinu-
cleotide synthetase (PP591) also play important roles
in pteridine biosynthesis.
By combining both differentially expressed lists 
of early- and late-stage clusters, we obtained 216
upregulated genes and nine downregulated genes.
Table 1 shows 50 upregulated genes selected from 
top of the list and nine downregulated genes. JUNB
appeared three times in the list, and was counted as 1.
Six out of nine downregulated genes were identified
as transcriptional factors. Of most interest were nu-
clear receptor subfamily genes (NR4A1 and NR4A3).
The role of nuclear receptor subfamily genes in ovar-
ian cancer has not been clarified in previous reports.
These genes encode a member of the steroid/thyroid
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Figure 1. Comparison of benign, stage I and III ovarian
tumors/cancers using gene expression ratios derived from
complementary DNA microarray. A diagram illustrates results
of hierarchical cluster analysis, and is visualized by Treeview
software. Ovarian tissues consisted of 13 benign tumors,
seven stage I cancers, and 15 stage III cancers. The speci-
mens were clustered based on the variation of expression
ratios of 9,600 genes. Genes were clustered based on simi-
larity in their expression patterns among specimens. Each
column represents a tumor sample and each row represents
a single gene. The color reflects ratios of log2-based scale.
Green reflects lower-than-control levels of gene expression
in the specimen, whereas red indicates higher-than-control
levels of gene expression. The dendrogram is color-coded
according to the category of specimen (left illustration).
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hormone/retinoid receptor superfamily. The encoded
protein may act as a transcription factor. Mutations in
this gene have been associated with disorders related
to dopaminergic dysfunction, including Parkinson dis-
ease, schizophrenia, and manic depression18. SF-1, one
of its members, has been implicated as a key tran-
scriptional regulator of all ovarian steroidogenic genes
in vitro19,20.
Genes associated with cell growth, commonly upreg-
ulated in cancer tissues, might be capable of distin-
guishing early-stage from late-stage cancer because of
the difference in growth patterns. A total of 203 genes
for cell growth and maintenance were selected from
current microarray data sets (Web supplementary mate-
rials). Cluster analysis was performed, but no stage-
specific clusters were found. The growth-specific genes
were insufficient to discriminate clinical stages of ovar-
ian cancer, a finding consistent with previous reports.
To identify genes that showed distinct expression
between late-stage and early-stage cancer, we obtained
the differential data set by subtracting the averaged
early-stage ratios from each late-stage data set. The SAM
method identified 89 upregulated and 163 downregu-
lated known genes with a mean number of false posi-
tive of 0.4, false discovery rate of 0.04%, a delta of 2.05,
and a minimum fold change of 2.4 (Table 2).
Genes that discriminated late-stage cluster from
early-stage clusters showed alternating cell–cell sig-
naling, hormone activity, extracellular matrix, and cell
adhesion. Fibroblast growth factor 2 is a member of
the fibroblast growth factor family. Fibroblast growth
factor family members possess broad mitogenic and
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Table 1. Differentially expressed genes of ovarian tumor/cancers
LocusLink ID Name Symbol Early* Late†
10407 Sperm associated antigen 11 SPAG11 1.38 5.21 
4188 MyoD family inhibitor MDFI 3.03 5.11 
4726 NADH dehydrogenase (ubiquinone) Fe-S NDUFS6 2.94 4.67
protein 6, 13 kDa (NADH-coenzyme Q reductase)
2135 Exostoses (multiple)-like 2 EXTL2 3.04 3.79 
8518 Inhibitor of kappa light polypeptide gene enhancer IKBKAP 2.93 3.74
in B-cells, kinase complex-associated protein
51205 Lysophosphatidic acid phosphatase ACP6 3.68 3.54 
3251 Hypoxanthine phosphoribosyltransferase 1 HPRT1 2.76 3.31
(Lesch-Nyhan syndrome)
7029 Transcription factor Dp-2 TFDP2 2.73 3.06
(E2F dimerization partner 2)
5230 Phosphoglycerate kinase 1 PGK1 5.53 3.01
*Early-stage cancer (benign tumor and stage I cancer); †stage III cancer. NADH = reduced nicotinamide adenine dinucleotide.
Table 2. Candidate genes that discriminate late stage and early stage ovarian cancers
LocusLink ID Name Symbol Ratio*
57569 Rho GTPase activating protein 20 ARHGAP20 4.51
11143 MYST histone acetyltransferase 2 MYST2 3.92
10407 Sperm associated antigen 11 SPAG11 3.83
9154 Solute carrier family 28 (sodium-coupled SLC28A1 3.56
nucleoside transporter), member 1
896 Cyclin D3 CCND3 2.86
1020 Cyclin-dependent kinase 5 CDK5 2.82
5696 Proteasome (prosome, macropain) subunit, PSMB8 2.75
beta type, 8 (large multifunctional protease 7)
6337 Sodium channel, nonvoltage-gated 1 alpha SCNN1A 2.72
10669 Cell growth regulator with EF-hand domain 1 CGREF1 2.71
8938 BAI1-associated protein 3 BAIAP3 2.69
*mRNA expression ratio.
cell survival activities, and are involved in a variety 
of biologic processes, including embryonic develop-
ment, cell growth, morphogenesis, tissue repair, tumor
growth, and invasion. This protein is a wide-spectrum
mitogenic, angiogenic and neurotrophic factor, that
has been implicated in diverse biologic processes, such
as limb and nervous system development, angiogene-
sis, wound healing, and tumor growth21. Collagens are
among extracellular matrix components evidently more
downregulated at the late-stage cluster compared with
early-stage cluster tumors. Collagens also contribute
to the morphogenesis of late-stage cancers.
To validate gene expression scored by microarray
analysis, real-time RT-PCR was performed to the selected
genes from each cluster (Figure 2). GCH1, KRT18, H3F3A,
and MYBL2 were selected from Table 1, while MDFI,
ARP3BETA, COL16A1, and MLN were chosen from
Table 2. Genes selected from Table 1 were consistently
highly expressed. For the second gene group, a signifi-
cant difference in expression ratios between early- and
late-stage cancer tissues was observed. However, the
evidence alone is insufficient to indicate stage-specific
expression in ovarian cancer, even though this is con-
sistent with our cluster analysis.
We have shown that pathologic stages can be dis-
criminated by the gene ensemble, identified by expres-
sion profiles. The ensemble of stage-specific genes is
capable of distinguishing late-stage cancers from early-
stage cancer/tumors, thus providing diagnostic value
worthy of further exploration.
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